The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer

Neoplasms, Gastrointestinal Clinical Trial

Official title:

The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03076502
• Other study ID #: ctDNA-GI
• Status: Not yet recruiting
• Phase: N/A
• First received: March 5, 2017
• Last updated: March 10, 2017
• Start date: April 2017
• Est. completion date: April 2019

Study information

• Verified date: March 2017
• Source: RenJi Hospital
• Contact: Tao Chen, M.D.
• Phone: +8613601779874
• Email: dr_chentao78[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to evaluate the role of ct-DNA, PVT1 and reactive oxygen species (ROS) as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.

Description:

Epidemiological surveys showed a significant increasing trend of gastrointestinal and hepatobiliary pancreatic cancer in recent years. How can make an early diagnosis of gastrointestinal and liver cancer as well as prognostic evaluation and efficacy monitoring, has become the hotspot. "liquid biopsy", which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation.

ct-DNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the ct-DNA originates from tumoral tissue. Besides, ct-DNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer.

It is known that levels of cellular ROS correlate with the aggressiveness of tumour cells and prognosis of patients. Cancer cells with increased endogenous ROS stress are more sensitive to anticancer agents and high levels of ROS generated by chemotherapeutic agents can induce cell death. Hence, ROS levels before and after chemotherapy in cancer cells can be an early indicator of treatment efficacy, which has the potential to shed new light on the choice of cancer therapy.

This study aims to evaluate the role of ct-DNA and ROS as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with suspected of gastrointestinal and hepatobiliary pancreatic cancer

• Age from 18 - 80 years

• No serious organic and mental illness;

Exclusion Criteria:

• Pregnancy

• No pathologic result

• Suffering other malignancies at the same time.

Related Conditions & MeSH terms

• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Neoplasms, Gastrointestinal
• Pancreatic Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
RenJi Hospital	Shanghai Changzheng Hospital, The University of Queensland

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological diagnosis	Sensitivity and specificity	intraoperative
Secondary	Tumor status(worse/ maintain/ better)	the level of ct-DNA compared with the tumor burden	2 years